The release of abuse-deterrent OxyContin and adolescent heroin use - DiNardi M.
OBJECTIVE: To determine the association between the abuse-deterrent reformulation of OxyContin and adolescent lifetime heroin use in the United States. METHODS: The quasi-experimental study uses individual survey data from the 1999-2019 Youth Risk ... (Source: SafetyLit)
Source: SafetyLit - October 15, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Opioid Prescriptions After Mohs Surgery Dropped Over Last Decade Opioid Prescriptions After Mohs Surgery Dropped Over Last Decade
' The switch from very addictive opioids like hydrocodone and oxycodone to weaker opioids like tramadol was fascinating to see, ' one of the investigators said.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 5, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Appeals Are Mounting in Purdue Pharma Bankruptcy Settlement Appeals Are Mounting in Purdue Pharma Bankruptcy Settlement
Objections to a settlement with Purdue Pharma are mounting in the form of appeals, with Rhode Island ' s attorney general saying the plan doesn ' t hold the OxyContin maker or its owners accountable.Associated Press (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2021 Category: Neurology Tags: Psychiatry News Source Type: news

Use of OxyContin Profits to Fight Opioids Formally Approved Use of OxyContin Profits to Fight Opioids Formally Approved
A judge formally approved a plan Friday to turn OxyContin maker Purdue Pharma into a new company no longer owned by members of the Sackler family. Its profits would go to fight the opioid epidemic.Associated Press (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 20, 2021 Category: Neurology Tags: Psychiatry News Source Type: news

Patterns, trends and determinants of medical opioid utilization in Canada 2005-2020: characterizing an era of intensive rise and fall - Jones W, Kaoser R, Fischer B.
BACKGROUND: Into the 21st century, the conflation of high rates of chronic pain, systemic gaps in treatment availability and access, and the arrival of potent new opioid medications (e.g., slow-release oxycodone) facilitated strong increases in medical opi... (Source: SafetyLit)
Source: SafetyLit - September 20, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

The Pain Wouldn ’t Stop — Because Her Medication Had Been Stolen
Too often, seniors who use opioids become targets for exploitation and abuse. (Source: NYT Health)
Source: NYT Health - September 17, 2021 Category: Consumer Health News Authors: Paula Span Tags: your-feed-science Drug Abuse and Traffic Drugs (Pharmaceuticals) Pain-Relieving Drugs Elderly Opioids and Opiates OxyContin (Drug) your-feed-health your-feed-healthcare Source Type: news

South Hills Pharmacist Pleads to Health Care Fraud Conspiracy, Fraudulently Obtaining Controlled Substances and Misbranding Drugs
FDA OCI, Timothy Forester, Venetia PA, South Hills pharmacist, health care fraud, conspiracy, controlled substances, misbranded drugs, Century Square Pharmacy, West Mifflin PA, Prescription Center Plus, oxycodone, hydrocodone, deception, obtain, no records, dispensed, generic drugs, relabeled, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - September 17, 2021 Category: Medical Law Authors: DOJ Source Type: news

U.S. Seeks to Block Bankruptcy Plan That Would Free Sacklers From Opioid Claims
The Justice Department has been appealing the deal, approved earlier this month. (Source: NYT Health)
Source: NYT Health - September 17, 2021 Category: Consumer Health News Authors: Katie Benner Tags: Suits and Litigation (Civil) Pain-Relieving Drugs Bankruptcies OxyContin (Drug) Justice Department Purdue Pharma Drain, Robert D Sackler Family Source Type: news

First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School. Funded by a grant from the National Institutes of Health, the trial will test the safety and potential efficacy of a vaccine that is designed to selectively prevent the euphoric and toxic effects of oxycodone. (Source: World Pharma News)
Source: World Pharma News - September 7, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Deal With OxyContin Maker Leaves Families Angry, Conflicted Deal With OxyContin Maker Leaves Families Angry, Conflicted
A bankruptcy judge conditionally approved a settlement with Purdue Pharma worth an estimated $10 billion on Wednesday. It was a deal that left many families feeling they didn ' t get what they really wanted.Associated Press (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 3, 2021 Category: Drugs & Pharmacology Tags: Psychiatry News Source Type: news

OxyContin Maker Purdue Pharma Is Dissolved
Sackler family to pay $4.5 billion in bankruptcy settlement, denies any personal responsibility (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - September 3, 2021 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Emergency Medicine, Pharmacy, Psychiatry, Anesthesiology & amp; Pain, Institutional, Source Type: news

OxyContin Maker Purdue Pharma Is Dissolved
THURSDAY, Sept. 2, 2021 -- Purdue Pharma was dissolved on Wednesday and the Sackler family will pay $4.5 billion under a bankruptcy settlement that will end thousands of lawsuits brought against the company over the U.S. opioid crisis. Purdue was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2021 Category: Pharmaceuticals Source Type: news

Deal with OxyContin maker leaves families angry, conflicted
A landmark settlement in the nation’s opioid epidemic is forcing the owners of OxyContin maker Purdue Pharma to give up the company and pay out $4.5 billion (Source: ABC News: Health)
Source: ABC News: Health - September 2, 2021 Category: Consumer Health News Tags: Health Source Type: news

Oxycontin Maker Purdue Dissolved, Family to Pay $4.5 Billion in Bankruptcy Settlement
THURSDAY, Sept. 2, 2021 -- Purdue Pharma was dissolved on Wednesday and the Sackler family will pay $4.5 billion under a bankruptcy settlement that will end thousands of lawsuits brought against the company over the United States ' opioid... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 2, 2021 Category: General Medicine Source Type: news

Judge conditionally approves plan to dissolve OxyContin maker Purdue Pharma
A federal bankruptcy judge ruled that Purdue Pharma, the maker of the addictive painkiller OxyContin, will be dissolved under a... (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2021 Category: Consumer Health News Source Type: news